Literature DB >> 22210246

The decline in yolk progesterone concentrations during incubation is dependent on embryonic development in the European starling.

Ryan T Paitz1, Joseph M Casto.   

Abstract

Oviparous amniotes, particularly birds, have become model systems in which to study how mothers may utilize steroids to adaptively adjust offspring development. Although there is now ample evidence that maternally derived steroids in the egg at oviposition can influence offspring phenotype, very little is known about how these steroids elicit such effects. Of the major avian steroid hormones found in yolk, progesterone is by far the most abundant at oviposition, but has received little research attention to date. In this study, we examine the metabolism of [(3)H]-progesterone injected into freshly laid European starling eggs throughout the first 5 days of development by characterization of radioactivity within the egg homogenate. We also introduce a technique that utilizes a focal, freeze/thaw cycle to prevent embryonic development and allows us to assess the role of the embryo in metabolizing progesterone during early incubation. Two major findings result. First is that [(3)H]-progesterone is metabolized in eggs possessing a developing embryo, but not in eggs with disrupted embryonic development. Second is that the change in the distribution of radioactivity within eggs possessing an embryo is the result of metabolism of [(3)H]-progesterone to a more polar form that is subsequently conjugated. Together, these data suggest live embryos are necessary for metabolism of progesterone during early incubation, underscoring the potentially important contribution of embryos to functional modulation or mediation of maternal yolk steroid effects.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22210246     DOI: 10.1016/j.ygcen.2011.12.014

Source DB:  PubMed          Journal:  Gen Comp Endocrinol        ISSN: 0016-6480            Impact factor:   2.822


  8 in total

1.  In ovo metabolism and yolk glucocorticoid concentration interact to influence embryonic glucocorticoid exposure patterns.

Authors:  Brian G Vassallo; Hannah P Litwa; Mark F Haussmann; Ryan T Paitz
Journal:  Gen Comp Endocrinol       Date:  2018-11-27       Impact factor: 2.822

2.  Evidence of embryonic regulation of maternally derived yolk corticosterone.

Authors:  Amanda W Carter; Rachel M Bowden; Ryan T Paitz
Journal:  J Exp Biol       Date:  2018-11-14       Impact factor: 3.312

3.  Changes in the concentrations of four maternal steroids during embryonic development in the threespined stickleback (Gasterosteus aculeatus).

Authors:  Ryan Thomas Paitz; Brett Christian Mommer; Elissa Suhr; Alison Marie Bell
Journal:  J Exp Zool A Ecol Genet Physiol       Date:  2015-06-02

4.  Immune activation generates corticosterone-mediated terminal reproductive investment in a wild bird.

Authors:  E Keith Bowers; Rachel M Bowden; Scott K Sakaluk; Charles F Thompson
Journal:  Am Nat       Date:  2015-04-01       Impact factor: 3.926

5.  In ovo inhibition of steroid metabolism by bisphenol-A as a potential mechanism of endocrine disruption.

Authors:  Sandrine G Clairardin; Ryan T Paitz; Rachel M Bowden
Journal:  Proc Biol Sci       Date:  2013-09-04       Impact factor: 5.349

6.  Maternally derived hormones, neurosteroids and the development of behaviour.

Authors:  James C Mouton; Renée A Duckworth
Journal:  Proc Biol Sci       Date:  2021-01-27       Impact factor: 5.349

7.  Characterizing the distribution of steroid sulfatase during embryonic development: when and where might metabolites of maternal steroids be reactivated?

Authors:  Ryan T Paitz; Kristin R Duffield; Rachel M Bowden
Journal:  J Exp Biol       Date:  2017-10-26       Impact factor: 3.312

8.  Gonadal steroid levels in rock pigeon eggs do not represent adequately maternal allocation.

Authors:  Neeraj Kumar; Martijn van Faassen; Bonnie de Vries; Ido Kema; Manfred Gahr; Ton G G Groothuis
Journal:  Sci Rep       Date:  2018-07-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.